Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Ambrx, Inc.
Scientific Title
A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens